trial

Risperidone-controlled,Multicentre Clinical Trial of Iloperidone in Patients With Schizophrenia

NCTId NCT02453893
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Unknown
Enrollment 288 (estimated)
Sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Primary completion 2015-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Unknown
Enrollment
288 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2013-11
Primary completion
2015-06
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
IloperidoneRisperidone

Sponsors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Lead Sponsor

Investigators

1
Li hua fang, Ph.DStudy Director

Sites

1 total
Shanghai, China

Linked catalysts

1
Risperidone-controlled,Multicentre Clinical Trial of Iloperidone in Patients Wit — primary completion2015-06

Facts & assertions

4 sourced
Enrollment
288
Phase
PHASE3
Primary Completion Date
2015-06
Status
UNKNOWN
relationships
The graph out of here
drug
Iloperidone
drug
Risperidone
drug
lead_sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Li hua fang, Ph.D
person